Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome in advanced solid tumors
NCT05086822Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2014
- Primary completion
- Aug 2017
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan liposome in solid tumor, sponsored by Hengrui. Primary endpoints: Adverse Event (AE), Dose Limiting Toxicities at 21 days and 1 more. Started Sep 2014; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05086822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086822.